Genomic Study of Relapse Esophageal Cancer After Radiotherapy
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Tumor tissue of patients received radiotherapy with diagnosis of recurrence between Jan 1, 2010 and Dec 1, 2020 were collected retrospectively. Recurrence tumor tissue is collected between Dec 31, 2020 and Dec 31, 2022 prospectively. Blood and preradiotherapy tumor tissue were also collected to be as contrast. A total of 100 paired blood, preradiotherapy tumor tissue and relapse tumor tissue were collected. What is more, a total of 100 paired blood and preradiotherapy tumor tissue with diagnosis of no recurrence were collected. All samples were conducted with whole exome sequencing.
Here the investigators define recurrence period as within 2 years and no recurrence period as more than 3 years after radiotherapy.
Criteria of relapse: (1) pathologic diagnosis is squamous carcinoma before radiotherapy;(2) received radiotherapy; (3)pathologic diagnosis is also squamous carcinoma after radiotherapy; (4) clinical symptoms including feeding obstruction etc; (5) imaging evidence showed disease progression.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Forventet)
Tilmelding
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Kuaile Zhao, doctor
- Telefonnummer: 18017312534
- E-mail: kuaile_z@sina.com
Undersøgelse Kontakt Backup
- Navn: Jiaying Deng, doctor
- Telefonnummer: 18317088158
- E-mail: dengjiaying3@sina.com
Studiesteder
-
-
-
Shanghai, Kina, 200032
- Rekruttering
- Fudan University Shanghai Cancer Center
-
Kontakt:
- Kuaile Zhao, doctor
- Telefonnummer: 18017312534
- E-mail: kuaile_z@sina.com
-
Kontakt:
- Jiaying Deng, doctor
- Telefonnummer: 18317088158
- E-mail: dengjiaying3@sina.com
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Barn
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Recurrence group: 100 paired relapsed tumor tissue,blood and preradiotherapy tumor tissue within 2 years after radiotherapy were collected.
No recurrence group:100 paired blood and preradiotherapy tumor tissue with more than 3 years after radiotherapy were collected
Beskrivelse
Inclusion Criteria:
- pathologic diagnosis is squamous cell carcinoma before radiotherapy;
- pathologic diagnosis is squamous cell carcinoma after radiotherapy;
- received radiotherapy
- clinical symptoms including dysphagia, feeding obstruction, etc
- image evidence showed disease progression
- the period of recurrence was within 2 years after radiotherapy
Exclusion Criteria:
- pathologic diagnosis is not squamous cell carcinoma before radiotherapy;
- pathologic diagnosis is not squamous cell carcinoma after radiotherapy
- not received radiotherapy
- the period of recurrence was more than 2 years after radiotherapy
- the period of no recurrence was within 3 years after radiotherapy
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: Case-Control
- Tidsperspektiver: Fremadrettet
Antal grupper/kohorter
Kohorter og interventioner
Gruppe / kohorteGruppe / kohorte |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Recurrence
The period of recurrence was within 2 years after radiotherapy.
Pathologic diagnosis was squamous cell carcinoma same with preradiotherapy.
|
To seek genomic characteristics of relapsed esophageal cancer with whole exome sequence.
|
|
No recurrence
The period was more than 3 years after radiotherapy and no recurrence signs were observed.
|
To seek genomic characteristics of relapsed esophageal cancer with whole exome sequence.
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
genomic characteristics of relapsed esophageal cancer
Tidsramme: through study completion, an average of 1 year
|
gene mutations, copy number variants
|
through study completion, an average of 1 year
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Efterforskere
Efterforskere
- Ledende efterforsker: Kuaile Zhao, doctor, Fudan University
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Forventet)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- ESO-shanghai 6
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .